Tiffany Peraino
Physician Assistant · Temescal Valley, CANPI 1124457015
Payments from drug & device makers
Across 449 payments — averaging $18.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$2K
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$835
- Boehringer Ingelheim$702
- Mylan Specialty L.p.$424
- Sanofi$356
- plus $2K from 28 others
What the payments were for
- Food & beverage$8,26497%
- Education$2573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 124 | $2,004 |
| AstraZeneca | 75 | $1,723 |
| Actelion Pharmaceuticals US, Inc. | 65 | $835 |
| Boehringer Ingelheim | 39 | $702 |
| Mylan Specialty L.p. | 17 | $424 |
| Sanofi | 17 | $356 |
| Baxter Healthcare | 12 | $325 |
| Insmed, Inc. | 13 | $287 |
| Regeneron Healthcare Solutions, Inc. | 8 | $274 |
| Genentech USA, Inc. | 16 | $243 |
| United Therapeutics Corporation | 7 | $146 |
| Bayer | 7 | $112 |
| AbbVie | 4 | $100 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Viiv Healthcare Company | 3 | $93 |
| Novartis | 4 | $92 |
| Grifols USA, LLC | 4 | $91 |
| Inspire Medical Systems, Inc. | 3 | $90 |
| Amgen | 3 | $81 |
| Jazz Pharmaceuticals Inc. | 3 | $58 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Johnson & Johnson | 3 | $42 |
| Shionogi Inc | 2 | $42 |
| Electromed, Inc. | 6 | $38 |
| Harmony Biosciences LLC | 1 | $31 |
| Paratek Pharmaceuticals, Inc. | 1 | $31 |
| Philips North America LLC | 2 | $26 |
| Phadia US Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $22 |
| Mayne Pharma Commercial LLC | 1 | $19 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $19 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Melinta Therapeutics, LLC | 1 | $17 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,522 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 71 | $428,004 |
| UptraviSelexipag | 19 | $379,341 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 377 | $330,571 |
| AdempasRiociguat | 22 | $281,949 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 15 | $219,972 |
| OpsumitMacitentan | 16 | $184,365 |
| OfevNintedanib Esylate | 13 | $169,827 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $147,477 |
| LetairisAmbrisentan | 11 | $139,931 |
| XolairOmalizumab | 19 | $116,099 |
| Orenitram ErTreprostinil Diolamine | 24 | $105,249 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 95 | $71,980 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 112 | $65,788 |
| Spiriva RespimatTiotropium Bromide | 50 | $50,066 |
| Breo ElliptaFluticasone/Vilanterol | 60 | $34,762 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $2,004 | $865,017633 claims |
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $835 | $563,70635 claims |
| BayerAdempas | $112 | $281,94922 claims |
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat, Combivent Respimat | $702 | $257,511117 claims |
| Insmed, Inc.Arikayce | $287 | $219,97215 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,723 | $85,023130 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $18 | $4,15211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.
Other physician assistant in Temescal Valley
- John QuigleyDowney$2.9M
- Andrea NguyenIrvine$1M
- Mikhail AlperMadera$889K
- Erin JensenUpland$716K
- Franklin ClineSacramento$458K
- Carla CrespoMarina del Rey$297K
- Katherine OsakiEl Centro$274K
- Shawna JonesFountain Valley$266K
- Heather AustinSalinas$219K
- Eric CheungLos Angeles$213K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.